HIV-associated conditions
Include HIV-associated neurocognitive disorder (HAND), drug adverse effect, or therapy-related immune reconstitution inflammatory syndrome (IRIS).
HIV-associated neurocognitive disorder
Represents a spectrum of progressive neurocognitive impairment ranging from asymptomatic neurocognitive impairment (ANI) to HIV-associated dementia (HAD):[14]Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007 Oct 30;69(18):1789-99.
http://www.ncbi.nlm.nih.gov/pubmed/17914061?tool=bestpractice.com
[23]Horberg M, Thompson M, Agwu A, et al. Primary care guidance for providers of care for persons with human immunodeficiency virus: 2024 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2024 Oct 12:ciae479.
https://www.doi.org/10.1093/cid/ciae479
http://www.ncbi.nlm.nih.gov/pubmed/39393187?tool=bestpractice.com
By definition, these conditions are only diagnosed if the impairment is not occurring as part of a delirium secondary to infection or drug effects, and cannot be explained by alternative aetiologies.[14]Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007 Oct 30;69(18):1789-99.
http://www.ncbi.nlm.nih.gov/pubmed/17914061?tool=bestpractice.com
Drug adverse effect or therapy-related IRIS
ART may induce cognitive or psychiatric problems directly as an adverse effect or indirectly through their effect on the immune system. The non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz is associated with the development of neuropsychiatric adverse effects, especially in the first weeks of treatment.[24]Blanch J, Martínez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):336-43.
http://www.ncbi.nlm.nih.gov/pubmed/11468421?tool=bestpractice.com
[25]Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials. 2005 Jul-Aug;6(4):187-96.
http://www.ncbi.nlm.nih.gov/pubmed/16214735?tool=bestpractice.com
[26]Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. AIDS Rev. 2010 Apr-Jun;12(2):67-75.
http://www.ncbi.nlm.nih.gov/pubmed/20571601?tool=bestpractice.com
[27]Cavalcante GI, Capistrano VL, Cavalcante FS, et al. Implications of efavirenz for neuropsychiatry: a review. Int J Neurosci. 2010 Dec;120(12):739-45.
http://www.ncbi.nlm.nih.gov/pubmed/20964556?tool=bestpractice.com
[28]Decloedt EH, Maartens G. Neuronal toxicity of efavirenz: a systematic review. Expert Opin Drug Saf. 2013 Nov;12(6):841-6.
http://www.ncbi.nlm.nih.gov/pubmed/23889591?tool=bestpractice.com
Rates of similar neuropsychiatric adverse effects are significantly lower with other NNRTI agents such as nevirapine, etravirine, and rilpivirine.[29]Cohen CJ, Andrade-Villanueva J, Clotet B, et al; THRIVE Study Group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011 Jul 16;378(9787):229-37.
http://www.ncbi.nlm.nih.gov/pubmed/21763935?tool=bestpractice.com
[30]Katlama C, Haubrich R, Lalezari J, et al; DUET-1, DUET-2 Study Groups. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009 Nov 13;23(17):2289-300.
http://www.ncbi.nlm.nih.gov/pubmed/19710593?tool=bestpractice.com
The integrase inhibitor raltegravir has been associated with infrequent neuropsychiatric adverse effects, and dolutegravir may be associated with insomnia and other central nervous system (CNS) effects.[31]Madeddu G, Menzaghi B, Ricci E, et al. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. AIDS. 2012 Nov 28;26(18):2412-5.
http://www.ncbi.nlm.nih.gov/pubmed/23032413?tool=bestpractice.com
[32]Harris M, Larsen G, Montaner JG. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008 Sep 12;22(14):1890-2.
http://www.ncbi.nlm.nih.gov/pubmed/18753871?tool=bestpractice.com
[33]Gray J, Young B. Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review. AIDS Patient Care STDs. 2009 Sep;23(9):689-90.
http://www.ncbi.nlm.nih.gov/pubmed/19663717?tool=bestpractice.com
[34]Walmsley SL, Antela A, Clumeck N, et al; SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013 Nov 7;369(19):1807-18.
http://www.nejm.org/doi/full/10.1056/NEJMoa1215541#t=article
http://www.ncbi.nlm.nih.gov/pubmed/24195548?tool=bestpractice.com
[35]Lepik KJ, Yip B, Ulloa AC, et al. Adverse drug reactions to integrase strand transfer inhibitors. AIDS. 2018 Apr 24;32(7):903-12.
http://www.ncbi.nlm.nih.gov/pubmed/29424784?tool=bestpractice.com
[36]van den Berk G, Oryszczyn J, Blok W, et al. Unexpectedly high rate of intolerance for dolutegravir in real life setting. Poster 948 presented at CROI 2016. February 2016 [internet publication].
http://www.croiconference.org/sessions/unexpectedly-high-rate-intolerance-dolutegravir-real-life-setting
Patients receiving ART may develop IRIS as a consequence of the reaction of a restored immune system to infectious agents. Commonly implicated infectious agents include Mycobacterium tuberculosis or M avium complex, although other causes (e.g., herpes simplex virus [HSV], varicella zoster virus [VZV], progressive multifocal leukoencephalopathy [human polyomavirus 2, also known as John Cunningham virus [JCV]], cytomegalovirus [CMV], cryptococcal infection and Toxoplasmosis gondii) are also recognised triggers.[37]Torok ME, Kambugu A, Wright E. Immune reconstitution disease of the central nervous system. Curr Opin HIV AIDS. 2008 Jul;3(4):438-45.
http://www.ncbi.nlm.nih.gov/pubmed/19373003?tool=bestpractice.com
[38]Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):130-4.
http://www.ncbi.nlm.nih.gov/pubmed/19365271?tool=bestpractice.com
[39]McCombe JA, Auer RN, Maingat FG, et al. Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology. 2009 Mar 3;72(9):835-41.
http://www.ncbi.nlm.nih.gov/pubmed/19255411?tool=bestpractice.com
Non-HIV-associated conditions
Comprise systemic comorbidities and psychiatric comorbidities.
Systemic comorbidities
Concomitant nutritional deficiency (e.g., folate, vitamin B12, vitamin D) may cause cognitive impairment, which may be seen in the setting of malnutrition in advanced HIV/AIDS.[40]The Mind Exchange Working Group. Assessment, diagnosis and treatment of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND): a consensus report of the Mind Exchange Program. Clin Infect Dis. 2013 Apr;56(7):1004-17.
http://www.ncbi.nlm.nih.gov/pubmed/23175555?tool=bestpractice.com
People with advanced HIV infection are at an increased risk of ischaemic stroke compared with people without HIV.[41]Sico JJ, Chang CC, So-Armah K, et al; Veterans Aging Cohort Study. HIV status and the risk of ischemic stroke among men. Neurology. 2015 May 12;84(19):1933-40.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433456
http://www.ncbi.nlm.nih.gov/pubmed/25862803?tool=bestpractice.com
The underlying pathogenesis varies and includes cerebral emboli secondary to cardiac disease, accelerated atherosclerosis, or cerebral vasculitis as a consequence of syphilis or amfetamine/cocaine use.
People living with HIV with concomitant hepatitis C infection have higher rates of cognitive impairment.[40]The Mind Exchange Working Group. Assessment, diagnosis and treatment of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND): a consensus report of the Mind Exchange Program. Clin Infect Dis. 2013 Apr;56(7):1004-17.
http://www.ncbi.nlm.nih.gov/pubmed/23175555?tool=bestpractice.com
[42]Hinkin CH, Castellon SA, Levine AJ, et al. Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis. 2008;27(2):11-7.
http://www.ncbi.nlm.nih.gov/pubmed/18681187?tool=bestpractice.com
Thyroid disease and hypogonadism are more common in people with HIV, and can represent an underlying cause of altered mental status.[40]The Mind Exchange Working Group. Assessment, diagnosis and treatment of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND): a consensus report of the Mind Exchange Program. Clin Infect Dis. 2013 Apr;56(7):1004-17.
http://www.ncbi.nlm.nih.gov/pubmed/23175555?tool=bestpractice.com
[43]Nelson M, Powles T, Zeitlin A, et al. Thyroid dysfunction and relationship to antiretroviral therapy in HIV-positive individuals in the HAART era. J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):113-4.
http://www.ncbi.nlm.nih.gov/pubmed/19092451?tool=bestpractice.com
[44]Lortholary O, Christeff N, Casassus P, et al. Hypothalamo-pituitary-adrenal function in human immunodeficiency virus-infected men. J Clin Endocrinol Metab. 1996 Feb;81(2):791-6.
http://www.ncbi.nlm.nih.gov/pubmed/8636305?tool=bestpractice.com
[45]Mayo J, Collazos J, Martínez E, et al. Adrenal function in the human immunodeficiency virus-infected patient. Arch Intern Med. 2002 May 27;162(10):1095-8.
http://archinte.jamanetwork.com/article.aspx?articleid=211446
http://www.ncbi.nlm.nih.gov/pubmed/12020177?tool=bestpractice.com
Psychiatric comorbidities
Psychiatric comorbidities are highly prevalent in people living with HIV and can contribute to cognitive difficulties.[40]The Mind Exchange Working Group. Assessment, diagnosis and treatment of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND): a consensus report of the Mind Exchange Program. Clin Infect Dis. 2013 Apr;56(7):1004-17.
http://www.ncbi.nlm.nih.gov/pubmed/23175555?tool=bestpractice.com
These include:[23]Horberg M, Thompson M, Agwu A, et al. Primary care guidance for providers of care for persons with human immunodeficiency virus: 2024 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2024 Oct 12:ciae479.
https://www.doi.org/10.1093/cid/ciae479
http://www.ncbi.nlm.nih.gov/pubmed/39393187?tool=bestpractice.com
[40]The Mind Exchange Working Group. Assessment, diagnosis and treatment of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND): a consensus report of the Mind Exchange Program. Clin Infect Dis. 2013 Apr;56(7):1004-17.
http://www.ncbi.nlm.nih.gov/pubmed/23175555?tool=bestpractice.com
Depression
Anxiety
Alcohol and substance use disorders
Cognitive impairment due to polypharmacy from prescription medications, in particular those with anticholinergic properties and psychotropic medications